1
7
1
↑1
↓7
—1
Evidence suggests Psilocybin maydecreaseDepressive symptoms.
5 studies (9 claims)
Typical dose 25 mg
Exact normalized-entity scope. Exact scope. Claims must match the selected normalized intervention and endpoint IDs; signal links are not expanded. Direction describes the stored endpoint phrase and is not a benefit/harm judgement.
9 of 9
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| psilocybin | Decreases - causes a significant reduction in | depressive symptoms | Human | participants in larger Phase II trials | Single 25 mg dose mentioned in the largest clinical trial. | Psychedelic Therapy: A Primer for Primary Care Clinicians-Psilocybin.cited 7× |
| psilocybin | Increases - was effective in improving | depressive symptoms | Human | patients with MDD | Not specified in the abstract. | Psilocybin for major depressive disorder: a systematic review of randomized controlled studies.cited 3× |
| psilocybin | Decreases - were associated with large effect sizes | depressive symptoms | Human | adult patients with depressive symptoms | Not available | The association between study design and antidepressant effects in psychedelic-assisted therapy: A meta-analysis. |
| psilocybin | No effect - were not statistically significant | depressive symptoms | Human | adult patients with depressive symptoms | Not available | The association between study design and antidepressant effects in psychedelic-assisted therapy: A meta-analysis. |
| psilocybin | Decreases - showed a large effect size | depressive symptoms | Human | adult patients with depressive symptoms | Not available | The association between study design and antidepressant effects in psychedelic-assisted therapy: A meta-analysis. |
| psilocybin | Decreases - showed a large effect size | depressive symptoms | Human | adult patients with depressive symptoms | Not available | The association between study design and antidepressant effects in psychedelic-assisted therapy: A meta-analysis. |
| psilocybin | Decreases - demonstrate large depressive symptom improvements | depressive symptoms | Human | clinical trials | Not provided. | Preliminary Evidence of Sleep Improvements Following Psilocybin Administration, and their Involvement in Antidepressant Therapeutic Action. |
| psilocybin | Decreases - significantly decreased | depressive symptoms | Human | participants with severe treatment-resistant depression | 25 mg (single dose). | Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial.cited 3× |
| psilocybin | Decreases - significantly decreased | depressive symptoms | Human | participants with severe treatment-resistant depression | 25 mg (single dose). | Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial.cited 3× |